Delivery of Antisense Oligodeoxyribonucleotide Lipopolyplex Nanoparticles Assembled by Microfluidic Hydrodynamic Focusing

Overview

Journal J Control Release

Specialty Pharmacology

Date 2009 Sep 1

PMID 19716852

Citations 28

Authors

Chee Guan Koh

Xulang Zhang

Shujun Liu

Sharon Golan

Bo Yu

Xiaojuan Yang

Jingjiao Guan

Yan Jin

Yeshayahu Talmon

Natarajan Muthusamy

Kenneth K Chan

John C Byrd

Robert J Lee

Guido Marcucci

L James Lee

Affiliations

Soon will be listed here.

Abstract

A multi-inlet microfluidic hydrodynamic focusing (MF) system to prepare lipopolyplex (LP) containing Bcl-2 antisense deoxyoligonucleotide (ODN) was developed and evaluated. The lipopolyplex nanoparticles consist of ODN:protamine:lipids (1:0.3:12.5wt/wt ratio) and the lipids included DC-Chol:egg PC:PEG-DSPE (40:58:2mol/mol%). Using K562 human erythroleukemia cells, which contain an abundance of Bcl-2 and overexpression of transferrin receptors (TfR), and G3139 (oblimerson sodium or Genasense(TM)) as a model cell line and drug, respectively, the Bcl-2 down-regulation at the mRNA and protein levels as well as cellular uptake and apoptosis was compared between the conventional bulk mixing (BM) method and the MF method. The lipopolyplex size and surface charge were characterized by dynamic light scattering (DLS) and zeta potential (zeta) measurement, respectively, while the ODN encapsulation efficiency was determined by gel electrophoresis. Cryogenic transmission electron microscopy (Cryo-TEM) was used to determine the morphology of LPs. Our results demonstrated that MF produced LP nanoparticles had similar structures but smaller size and size distribution compared to BM LP nanoparticles. MF LP nanoparticles had higher level of Bcl-2 antisense uptake and showed more efficient down-regulation of Bcl-2 protein level than BM LP nanoparticles.

Citing Articles

Nucleic Acid Conjugates: Unlocking Therapeutic Potential.

Kashyap D, Booth M ACS Bio Med Chem Au. 2025; 5(1):3-15.

PMID: 39990950 PMC: 11843337. DOI: 10.1021/acsbiomedchemau.4c00092.

Microfluidic approaches for producing lipid-based nanoparticles for drug delivery applications.

Piunti C, Cimetta E Biophys Rev (Melville). 2024; 4(3):031304.

PMID: 38505779 PMC: 10903496. DOI: 10.1063/5.0150345.

Macrophage-Targeted Lipid Nanoparticle Delivery of microRNA-146a to Mitigate Hemorrhagic Shock-Induced Acute Respiratory Distress Syndrome.

Fei Q, Shalosky E, Barnes R, Shukla V, Xu S, Ballinger M ACS Nano. 2023; 17(17):16539-16552.

PMID: 37595605 PMC: 10754353. DOI: 10.1021/acsnano.3c01814.

Microfluidic Generation of Near-Infrared Photothermal Vitexin/ICG Liposome with Amplified Photodynamic Therapy.

Cao X, Liu Q, Adu-Frimpong M, Shi W, Liu K, Deng T AAPS PharmSciTech. 2023; 24(4):82.

PMID: 36949351 DOI: 10.1208/s12249-023-02539-2.

Liposomes for Tumor Targeted Therapy: A Review.

Wang S, Chen Y, Guo J, Huang Q Int J Mol Sci. 2023; 24(3).

PMID: 36768966 PMC: 9916501. DOI: 10.3390/ijms24032643.

References

Dias N, Stein C . Potential roles of antisense oligonucleotides in cancer therapy. The example of Bcl-2 antisense oligonucleotides. Eur J Pharm Biopharm. 2002; 54(3):263-9. DOI: 10.1016/s0939-6411(02)00060-7. View

Putaux J, Buleon A, Borsali R, Chanzy H . Ultrastructural aspects of phytoglycogen from cryo-transmission electron microscopy and quasi-elastic light scattering data. Int J Biol Macromol. 1999; 26(2-3):145-50. DOI: 10.1016/s0141-8130(99)00076-8. View

Seymour L . Passive tumor targeting of soluble macromolecules and drug conjugates. Crit Rev Ther Drug Carrier Syst. 1992; 9(2):135-87. View

Sato Y, Yamauchi N, Takahashi M, Sasaki K, Fukaura J, Neda H . In vivo gene delivery to tumor cells by transferrin-streptavidin-DNA conjugate. FASEB J. 2000; 14(13):2108-18. DOI: 10.1096/fj.99-1052com. View

Yang X, Koh C, Liu S, Pan X, Santhanam R, Yu B . Transferrin receptor-targeted lipid nanoparticles for delivery of an antisense oligodeoxyribonucleotide against Bcl-2. Mol Pharm. 2009; 6(1):221-30. PMC: 3608852. DOI: 10.1021/mp800149s. View

Otten A, Koster S, Struth B, Snigirev A, Pfohl T . Microfluidics of soft matter investigated by small-angle X-ray scattering. J Synchrotron Radiat. 2005; 12(Pt 6):745-50. DOI: 10.1107/S0909049505013580. View

Chiu S, Liu S, Perrotti D, Marcucci G, Lee R . Efficient delivery of a Bcl-2-specific antisense oligodeoxyribonucleotide (G3139) via transferrin receptor-targeted liposomes. J Control Release. 2006; 112(2):199-207. DOI: 10.1016/j.jconrel.2006.02.011. View

Weisman S, Hirsch-Lerner D, Barenholz Y, Talmon Y . Nanostructure of cationic lipid-oligonucleotide complexes. Biophys J. 2004; 87(1):609-14. PMC: 1304382. DOI: 10.1529/biophysj.103.033480. View

Koh C, Tan W, Zhao M, Ricco A, Fan Z . Integrating polymerase chain reaction, valving, and electrophoresis in a plastic device for bacterial detection. Anal Chem. 2003; 75(17):4591-8. DOI: 10.1021/ac0343836. View

10.

Kerkmann M, Lochmann D, Weyermann J, Marschner A, Poeck H, Wagner M . Immunostimulatory properties of CpG-oligonucleotides are enhanced by the use of protamine nanoparticles. Oligonucleotides. 2006; 16(4):313-22. DOI: 10.1089/oli.2006.16.313. View

11.

Jeffs L, Palmer L, Ambegia E, Giesbrecht C, Ewanick S, MacLachlan I . A scalable, extrusion-free method for efficient liposomal encapsulation of plasmid DNA. Pharm Res. 2005; 22(3):362-72. DOI: 10.1007/s11095-004-1873-z. View

12.

Banerjee D . Technology evaluation: G-3139. Curr Opin Mol Ther. 2001; 1(3):404-8. View

13.

Junghans M, Kreuter J, Zimmer A . Antisense delivery using protamine-oligonucleotide particles. Nucleic Acids Res. 2000; 28(10):E45. PMC: 105384. DOI: 10.1093/nar/28.10.e45. View

14.

Gewirtz A . Antisense oligonucleotide therapeutics for human leukemia. Curr Opin Hematol. 1998; 5(1):59-71. DOI: 10.1097/00062752-199801000-00011. View

15.

Link D, Anna S, Weitz D, Stone H . Geometrically mediated breakup of drops in microfluidic devices. Phys Rev Lett. 2004; 92(5):054503. DOI: 10.1103/PhysRevLett.92.054503. View

16.

Liu S, Liu Z, Xie Z, Pang J, Yu J, Lehmann E . Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/NF-kappaB-dependent DNA methyltransferase activity in acute myeloid leukemia. Blood. 2007; 111(4):2364-73. PMC: 2234064. DOI: 10.1182/blood-2007-08-110171. View

17.

Webb A, Cunningham D, Cotter F, Clarke P, Di Stefano F, Ross P . BCL-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet. 1997; 349(9059):1137-41. DOI: 10.1016/s0140-6736(96)11103-x. View

18.

Xu L, Pirollo K, Tang W, Rait A, Chang E . Transferrin-liposome-mediated systemic p53 gene therapy in combination with radiation results in regression of human head and neck cancer xenografts. Hum Gene Ther. 1999; 10(18):2941-52. DOI: 10.1089/10430349950016357. View

19.

Jahn A, Vreeland W, Gaitan M, Locascio L . Controlled vesicle self-assembly in microfluidic channels with hydrodynamic focusing. J Am Chem Soc. 2004; 126(9):2674-5. DOI: 10.1021/ja0318030. View

20.

Iversen P . In vivo studies with phosphorothioate oligonucleotides: pharmacokinetics prologue. Anticancer Drug Des. 1991; 6(6):531-8. View